Similar results in prostate cancer patients were reported with another PSMA-targeted tracer, OTL78, which could detect four out of seven conglomerate LNMs in vivo, also resulting in a sensitivity of 57.1% [39]. This evidence concerns the gene FOLH1 and prostate cancer.